Lck Inhibitor

A cell-permeable pyrrolopyrimidine compound that acts as a potent, reversible, selective, and ATP-competitive inhibitor of Lck (IC₅₀ at 5 µM ATP = <1 nM, 2 nM, 70 nM, 1.57 µM and 1.98 µM for lck_64-509 Y³⁹⁴, Lckcd pY³⁹⁴, Src, Kdr and Tie-2, respectively; IC₅₀ at 1 mM ATP = 16 µM, 66 nM, 126 nM, 420 nM and 5.18 µM for Lck_64-509 Y³⁹⁴, Blk, Fyn, Lyn and Csk, respectively). Only minimally affects the activities of other kinases (IC₅₀ = 3.2 µM, >33 µM, >50 µM and >50 µM for EGFR, PKC, CDC2/B and ZAP-70, respectively). Also shown to potently block T-cell receptor-stimulated IL-2 production in vitro (IC₅₀<1-40 nM in Jurkat T cells) and in vivo (ED₅₀ = 4 mg/kg in mice, ip.)

Primary Target
Lck₆₄₋₅₀₉ Y³⁹⁴

Target IC₅₀: At5 µM ATP = <1 nM, 2 nM, 70 nM, 1.57 µM and 1.98 µM for lck64-509 Y394, Lckcd pY394, Src, Kdr and Tie-2, respectively; IC50 at 1 mM ATP = 16 µM, 66 nM, 126 nM, 420 nM and 5.18 µM for Lck64-509 Y394, Blk, Fyn, Lyn and Csk

Toxicity: Harmful (C)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Burchat, A.F., et al. 2000. Bioorg. Med. Chem. Lett.10, 2171.
Arnold. L.D., et al. 2000. Bioorg. Med. Chem. Lett.10, 2167.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany